A Phase 2, Multicenter, Dose-Ranging Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C

Trial Profile

A Phase 2, Multicenter, Dose-Ranging Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs VX 135 (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 09 Jul 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
    • 13 Apr 2014 Results assessing the incidence of VX-135 resistance variants in patient who had relapsed presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
    • 30 Oct 2013 Status changed from active, no longer recruiting to suspended ( a clinical hold remains at doses higher than 100mg).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top